Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mohs Surgery | 7 | 2023 | 53 | 2.970 |
Why?
|
| Skin Neoplasms | 6 | 2023 | 403 | 2.260 |
Why?
|
| Skin Pigmentation | 4 | 2024 | 33 | 0.930 |
Why?
|
| Skin Aging | 2 | 2016 | 11 | 0.920 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2016 | 19 | 0.920 |
Why?
|
| Lasers, Solid-State | 4 | 2010 | 18 | 0.780 |
Why?
|
| Surgical Wound Infection | 2 | 2023 | 125 | 0.780 |
Why?
|
| Vitiligo | 4 | 2024 | 119 | 0.750 |
Why?
|
| Staphylococcal Infections | 1 | 2023 | 135 | 0.720 |
Why?
|
| Melanocytes | 3 | 2024 | 76 | 0.690 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 14 | 0.670 |
Why?
|
| Forehead | 1 | 2020 | 15 | 0.660 |
Why?
|
| Surgical Wound | 1 | 2020 | 10 | 0.660 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 35 | 0.660 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2020 | 35 | 0.650 |
Why?
|
| Extremities | 1 | 2021 | 62 | 0.640 |
Why?
|
| Dermatology | 1 | 2020 | 66 | 0.610 |
Why?
|
| Face | 2 | 2016 | 36 | 0.560 |
Why?
|
| Light | 2 | 2010 | 200 | 0.550 |
Why?
|
| Skin | 3 | 2012 | 414 | 0.540 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 260 | 0.530 |
Why?
|
| Melanoma | 1 | 2021 | 332 | 0.520 |
Why?
|
| Cicatrix | 4 | 2011 | 62 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 727 | 0.480 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2010 | 11 | 0.470 |
Why?
|
| Lasers, Gas | 1 | 2015 | 2 | 0.450 |
Why?
|
| Neuromuscular Agents | 1 | 2015 | 16 | 0.440 |
Why?
|
| Incontinentia Pigmenti | 1 | 2014 | 1 | 0.440 |
Why?
|
| Prospective Studies | 10 | 2023 | 3299 | 0.410 |
Why?
|
| Nail Diseases | 1 | 2014 | 49 | 0.410 |
Why?
|
| Acne Vulgaris | 2 | 2011 | 23 | 0.400 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2012 | 2 | 0.390 |
Why?
|
| Drug Eruptions | 1 | 2012 | 15 | 0.380 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 33 | 0.380 |
Why?
|
| Natural Killer T-Cells | 1 | 2012 | 30 | 0.370 |
Why?
|
| Immunophenotyping | 1 | 2012 | 194 | 0.360 |
Why?
|
| Middle Aged | 15 | 2024 | 18106 | 0.350 |
Why?
|
| Humans | 28 | 2024 | 64729 | 0.340 |
Why?
|
| Consensus | 2 | 2023 | 181 | 0.330 |
Why?
|
| Keratinocytes | 3 | 2024 | 71 | 0.320 |
Why?
|
| Low-Level Light Therapy | 1 | 2010 | 11 | 0.320 |
Why?
|
| Granuloma Annulare | 1 | 2009 | 3 | 0.310 |
Why?
|
| Ofloxacin | 1 | 2009 | 8 | 0.300 |
Why?
|
| Rifampin | 1 | 2009 | 24 | 0.300 |
Why?
|
| Minocycline | 1 | 2009 | 28 | 0.300 |
Why?
|
| Ultraviolet Rays | 1 | 2010 | 146 | 0.300 |
Why?
|
| Male | 15 | 2024 | 30790 | 0.260 |
Why?
|
| Skin Transplantation | 2 | 2024 | 154 | 0.260 |
Why?
|
| Pain | 2 | 2023 | 398 | 0.250 |
Why?
|
| Adult | 12 | 2024 | 17230 | 0.250 |
Why?
|
| Female | 16 | 2024 | 33739 | 0.240 |
Why?
|
| Administration, Cutaneous | 2 | 2015 | 31 | 0.230 |
Why?
|
| Transplantation, Autologous | 1 | 2024 | 128 | 0.210 |
Why?
|
| Incidence | 2 | 2020 | 1409 | 0.210 |
Why?
|
| Treatment Outcome | 8 | 2024 | 5758 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 801 | 0.190 |
Why?
|
| Scleroderma, Localized | 1 | 2023 | 11 | 0.190 |
Why?
|
| Dermatitis | 1 | 2023 | 27 | 0.190 |
Why?
|
| Young Adult | 6 | 2024 | 4771 | 0.180 |
Why?
|
| Blepharoplasty | 2 | 2013 | 6 | 0.180 |
Why?
|
| Postoperative Complications | 3 | 2023 | 1309 | 0.180 |
Why?
|
| Aged | 7 | 2016 | 14834 | 0.170 |
Why?
|
| Facial Neoplasms | 1 | 2020 | 7 | 0.170 |
Why?
|
| SEER Program | 1 | 2021 | 75 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 33 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2753 | 0.160 |
Why?
|
| Surgical Flaps | 1 | 2020 | 116 | 0.150 |
Why?
|
| Laser Therapy | 2 | 2010 | 39 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 433 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 664 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 369 | 0.140 |
Why?
|
| Injections | 2 | 2016 | 83 | 0.140 |
Why?
|
| Single-Blind Method | 3 | 2013 | 142 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2016 | 50 | 0.120 |
Why?
|
| Cryotherapy | 1 | 2015 | 16 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2023 | 2483 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 65 | 0.110 |
Why?
|
| United States | 2 | 2021 | 8041 | 0.110 |
Why?
|
| Erythema | 1 | 2015 | 11 | 0.110 |
Why?
|
| Photochemotherapy | 1 | 2015 | 46 | 0.110 |
Why?
|
| Facial Dermatoses | 1 | 2015 | 10 | 0.110 |
Why?
|
| Edema | 1 | 2015 | 42 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 105 | 0.110 |
Why?
|
| Eye | 1 | 2015 | 59 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 315 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 371 | 0.100 |
Why?
|
| Spectrum Analysis | 2 | 2012 | 50 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 456 | 0.100 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2012 | 2 | 0.100 |
Why?
|
| Oculomotor Muscles | 1 | 2013 | 11 | 0.100 |
Why?
|
| Acanthosis Nigricans | 1 | 2012 | 1 | 0.090 |
Why?
|
| Oxyhemoglobins | 1 | 2012 | 9 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1135 | 0.090 |
Why?
|
| Melanins | 1 | 2012 | 27 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 46 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 71 | 0.090 |
Why?
|
| Models, Immunological | 1 | 2012 | 86 | 0.090 |
Why?
|
| Biopsy | 2 | 2010 | 454 | 0.090 |
Why?
|
| Fibroblasts | 2 | 2024 | 414 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2012 | 136 | 0.090 |
Why?
|
| Rhytidoplasty | 1 | 2011 | 2 | 0.090 |
Why?
|
| Tissue Adhesives | 1 | 2010 | 7 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 666 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 640 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 134 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 51 | 0.080 |
Why?
|
| Inflammation | 2 | 2023 | 1185 | 0.080 |
Why?
|
| Cell Movement | 1 | 2012 | 475 | 0.080 |
Why?
|
| Hypertrichosis | 1 | 2010 | 4 | 0.080 |
Why?
|
| Hair Removal | 1 | 2010 | 8 | 0.080 |
Why?
|
| Suture Techniques | 1 | 2010 | 94 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 219 | 0.080 |
Why?
|
| Adolescent | 3 | 2023 | 6291 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 792 | 0.080 |
Why?
|
| Lasers, Dye | 1 | 2009 | 5 | 0.070 |
Why?
|
| Phenotype | 1 | 2012 | 1231 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 951 | 0.070 |
Why?
|
| Electromagnetic Fields | 1 | 2008 | 15 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 461 | 0.070 |
Why?
|
| Risk Factors | 2 | 2015 | 5393 | 0.070 |
Why?
|
| Fibrosis | 2 | 2023 | 171 | 0.070 |
Why?
|
| Biomarkers | 1 | 2013 | 1465 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 704 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 1633 | 0.060 |
Why?
|
| Ultraviolet Therapy | 1 | 2024 | 12 | 0.050 |
Why?
|
| Bleomycin | 1 | 2023 | 35 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2023 | 23 | 0.050 |
Why?
|
| Receptors, CXCR3 | 1 | 2023 | 35 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2023 | 56 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2023 | 373 | 0.040 |
Why?
|
| Ligands | 1 | 2023 | 416 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 5562 | 0.040 |
Why?
|
| Colorimetry | 1 | 2012 | 26 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 298 | 0.020 |
Why?
|
| Esthetics | 1 | 2010 | 18 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 16 | 0.020 |
Why?
|
| Axilla | 1 | 2010 | 18 | 0.020 |
Why?
|
| Groin | 1 | 2010 | 14 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 214 | 0.020 |
Why?
|
| Hair Follicle | 1 | 2010 | 34 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11085 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1555 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 21292 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 3745 | 0.010 |
Why?
|
| Child | 1 | 2012 | 4599 | 0.010 |
Why?
|
Mahmoud Abdallah's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(145)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_